[{"data":1,"prerenderedAt":153},["ShallowReactive",2],{"drug-tezepelumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":51,"warnings":61,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"usApproval":97,"links":103,"populations":118},"tezepelumab",1,{"fa":7,"en":8},"تزپلوماب","Tezepelumab","respiratory",{"fa":11,"en":12},"آنتی‌بادی ضد TSLP","Anti-TSLP antibody",[14],{"name":15,"market":16},"Tezspire","US",[18,19,7],"tezspire","تزسپایر",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"pfs-210","injection","sc","210 mg\u002F1.91 mL (110 mg\u002FmL) syringe, pen or vial",{"amount":27,"unit":28,"perVolumeMl":29},210,"mg",1.91,[16],[32],{"source":33,"section":34},"fda-tezspire","3",[36],{"id":37,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":47,"durationDays":50},"asthma",{"fa":39,"en":40},"آسم شدید (افزودنی، ۱۲ سال به بالا) — ۲۱۰ mg زیرجلدی هر ۴ هفته","Severe asthma (add-on, ≥12 y) — 210 mg SC every 4 weeks",{"minAge":42},{"value":43,"unit":44},12,"year","fixed",{"perDose":27,"dosesPerDay":5},[48],{"source":33,"section":49},"2.1",{"min":5,"max":5},[52],{"id":53,"severity":54,"text":55,"refs":58},"hyper","block",{"fa":56,"en":57},"حساسیت به تزپلوماب.","Hypersensitivity to tezepelumab.",[59],{"source":33,"section":60},"4",[62,69],{"text":63,"refs":66},{"fa":64,"en":65},"واکنش حساسیتی؛ برای حمله حاد آسم نیست؛ کورتیکواستروئید را ناگهانی قطع نکنید؛ عفونت کرمی پیش از شروع درمان شود.","Hypersensitivity; not for acute asthma; do not stop corticosteroids abruptly; treat helminth infection before starting.",[67],{"source":33,"section":68},"5",{"text":70,"refs":73},{"fa":71,"en":72},"واکسن زنده در طول درمان نه.","Avoid live attenuated vaccines.",[74],{"source":33,"section":75},"5.5",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":37,"formulation":22,"input":84,"expect":87},{"ageYears":85,"weightKg":86},40,70,{"perDose":27,"mlPerDose":29},[89],"R03DX11",{"status":91,"refs":92},"not-found",[93],{"source":94,"section":95,"url":96},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Tezepelumab",{"kind":98,"refs":99,"id":102},"BLA",[100],{"source":33,"section":101},"SPL approval \u002F marketing category","BLA761224",[104,107,111,115],{"kind":105,"url":106,"label":102},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=761224",{"kind":108,"url":109,"label":110},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=60f0aa03-ad25-4d48-80ce-7fcfa76f325f","FDA Tezspire",{"kind":112,"url":113,"label":114},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622010.html","Tezepelumab Injection",{"kind":116,"url":117,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=R03DX11",{"pregnancy":119,"lactation":128,"pediatric":136,"geriatric":144},{"level":120,"text":121,"quote":124,"refs":125},"caution",{"fa":122,"en":123},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.",[126],{"source":33,"section":127},"8.1",{"level":120,"text":129,"quote":132,"refs":133},{"fa":130,"en":131},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of tezepelumab-ekko in human milk, its effects on the breastfed infant, or its effects on milk production.",[134],{"source":33,"section":135},"8.2",{"level":120,"text":137,"quote":140,"refs":141},{"fa":138,"en":139},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Asthma The safety and effectiveness of TEZSPIRE for the add-on maintenance treatment of severe asthma have been established in pediatric patients aged 12 years and older [see Adverse Reactions (6.1) and Clinical Studies (14.1)] .",[142],{"source":33,"section":143},"8.4",{"level":145,"text":146,"quote":149,"refs":150},"ok",{"fa":147,"en":148},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness of TEZSPIRE have been observed between patients 65 years of age and older and younger patients [see Adverse Reactions (6.1) and Clinical Studies (14.1) ] .",[151],{"source":33,"section":152},"8.5",1792191569074]